Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults
Abstract
Objective: To study the acute and steady-state cognitive effects of three new antiepileptic drugs (AEDs): gabapentin, lamotrigine, and topiramate.
Background: Several newer antiepileptic medications approved recently by the Food and Drug Administration are gaining attention as efficacious alternatives to established AEDs. Greater tolerability with fewer side effects are reported in some. However, the potential cognitive effects of these newer AEDs have received limited attention.
Methods: Healthy young adults randomized to either of the three drugs were administered tests of attention, psychomotor speed, language, memory, and mood at baseline (predrug), acute single-dose period, and after 2 and 4 weeks on the drug.
Results: Compared with baseline, the topiramate group had selective, statistically significant declines on measures of attention and word fluency at acute doses, whereas the other two AED groups had no performance changes. At the 2- and 4-week test periods, only the topiramate subjects continued to display neurocognitive effects from drug administration.
Conclusions: Results demonstrate potential acute and steady-state adverse cognitive effects for topiramate, whereas minimal effects were displayed for either gabapentin or lamotrigine in young healthy adults.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Trimble MR, Reynolds EH. Anticonvulsant drugs and mental symptoms : a review. Psychol Med 1976;6:169–178.
2.
MacPhee GJA, Goldie C, Roulston D. Effect of carbamazepine on psychomotor performance in naive subjects. Eur J Clin Pharmacol 1986;30:37–42.
3.
Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology 1995;45:1494–1499.
4.
Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning. Arch Neurol 1996;53:1008–1016.
5.
Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic–clonic seizures. N Engl J Med 1985;313:145–151.
6.
Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic–clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study no. 264 Group. N Engl J Med 1992;327:765–771.
7.
Thompson PJ, Huppert F, Trimble MR. Phenytoin and cognitive functions : effects on normal volunteers and implications for epilepsy. Br J Psychol 1981;20:155–162.
8.
Thompson PJ, Trimble MR. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981;12:819–824.
9.
Petroff A, Rothman D, Behar K, Lamoureux D, Mattson R. The effects of GBP on brain GABA in patients with epilepsy. Ann Neurol 1996;39:95–98.
10.
White HS, Brown SD, Woodead JH, Skean GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167–179.
11.
Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284–2291.
12.
Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures : a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;34:113–121.
13.
Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition : a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997;62:372–376.
14.
Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476–479.
15.
Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312–322.
16.
Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684–1690.
17.
Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678–1683.
18.
Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial to topiramate (600 mg daily) for the treatment of refractory epilepsy. Epilepsia 1996;37:763–768.
19.
Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324–333.
20.
Faught E, French J, Harden C, Postmarketing Antiepileptic Drug Survey Group (PADS). Adverse effects of TPM : results from a large post-marketing survey. Epilepsia 1997;38 (suppl 8):97. Abstract.
21.
Kuzniecky R, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA in healthy humans. Neurology 1998;51:627–629.
22.
Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991;41:1537–1540.
23.
Gronwall D, Wrightson P. Delayed recovery of intellectual function after minor head injury. Lancet 1974;2:207–210.
24.
Smith A. Symbol Digit Modalities Test. Manual. Los Angeles:Western Psychological Services, 1973.
25.
Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;24:1019–1025.
26.
Benton AL, Hamsher KdeS. Multilingual aphasia examination. Iowa City, IA:AJA Associates, 1983.
27.
Lezak M. Neuropsychological assessment. 2nd ed. New York:Oxford University Press, 1996.
28.
McNair DM, Lorr M, Droppleman LF. Manual: Profile of Mood States–revised. San Diego, CA:Educational and Industrial Testing Service, 1992.
29.
Beydoun A, Fischer J, Labar DR, et al. A 26-week double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology 1997;49:746–752.
30.
SPSS.SamplePower. Chicago:SPSS, Inc., 1995.
31.
Faught E, Kuzniecky R, Gilliam F. Cognitive effects of TPM. Neurology 1997;48:A336. Abstract.
32.
Fitton A, Goa KL. Lamotrigine : an update of its pharmacology and therapeutic use in epilepsy. Drugs 1996;50:691–713.
33.
Pledger G, Reife R, Lim P, Karim R. Overview of TPM efficacy from adjunctive therapy trials. Epilepsia 1995;36 (suppl 3):S150. Abstract.
34.
Sharief M, Viteri C, Ben–Menachem E, et al. Double-blind, placebo-controlled study of TPM in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217–224.
35.
Tassinari C, Chauvel P, Chodkiewicz J, et al. Double-blind placebo-controlled trial of TPM (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:539–543.
36.
Ben–Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of TPM as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:763–768.
37.
Sachdeo RC, Riefe RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294–300.
38.
Dodrill CB, Wilensky AJ. Neuropsychological abilities before and after 5 years of stable antiepileptic drug therapy. Epilepsia 1992;33:327–334.
Information & Authors
Information
Published In
Copyright
© 1999.
Publication History
Received: June 23, 1998
Accepted: October 1, 1998
Published online: January 1, 1999
Published in print: January 1, 1999
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Neurohabilitation of Cognitive Functions in Pediatric Epilepsy Patients through LEGO®-Based Therapy, Brain Sciences, 14, 7, (702), (2024).https://doi.org/10.3390/brainsci14070702
- Topiramate, The American Psychiatric Association Publishing Textbook of Psychopharmacology, (2024).https://doi.org/10.1176/appi.books.9781615375523.as42
- Association between gabapentin use and risk of dementia in adults with chronic pain: A nested case-control study, Journal of Affective Disorders, 358, (205-210), (2024).https://doi.org/10.1016/j.jad.2024.05.031
- The effect of gabapentin and pregabalin administration on memory in clinical and preclinical studies: a meta-analysis and systematic review, BMC Psychiatry, 23, 1, (2023).https://doi.org/10.1186/s12888-023-04696-x
- Cognitive effect of antiseizure medications in medial temporal lobe epilepsy, European Journal of Neurology, 30, 12, (3692-3702), (2023).https://doi.org/10.1111/ene.16050
- LAMOTRIGINE FOR THE TREATMENT OF EPILEPSY WITH CONCOMITANT COGNITIVE, EMOTIONAL-VOLITIONAL AND BEHAVIORAL DISORDERS IN GIRLS, Ulyanovsk Medico-biological Journal, 2, (52-60), (2022).https://doi.org/10.34014/2227-1848-2022-2-52-60
- The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition, Frontiers in Pharmacology, 13, (2022).https://doi.org/10.3389/fphar.2022.910719
- Cognitive reawakening and improved quality of life achieved after discontinuing 16 years of anti-seizure treatment with topiramate, Neurocase, 28, 1, (102-106), (2022).https://doi.org/10.1080/13554794.2022.2032187
- The impact of perampanel on cognition: A systematic review of studies employing standardized tests in patients with epilepsy, Seizure, 94, (107-111), (2022).https://doi.org/10.1016/j.seizure.2021.12.001
- Migraine, Comprehensive Pharmacology, (548-589), (2022).https://doi.org/10.1016/B978-0-12-820472-6.00083-9
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.